Abstract
Rationale
Schizophrenia has been linked to dysregulation of dopamine and glutamate transmitter systems. Attempts to model aspects of schizophrenia in animals have made use of treatments that primarily affect dopaminergic (e.g., amphetamine, Amp) and glutamatergic (e.g., phencyclidine, PCP) function. In addition to exerting short-term acute effects, these agents also induce long-term effects, as seen, for example, in neurochemical and behavioural sensitization.
Objectives
The goal of this work was to compare Amp- and PCP-sensitized states on two measures of information processing that are impaired in schizophrenia, prepulse inhibition (PPI) of the acoustic startle reflex and latent inhibition (LI).
Methods
Rats received injections of Amp, PCP or saline 3 days per week for 3 weeks. The Amp dose increased from 1 to 3 mg/kg, at the rate of 1 mg/kg each week. The PCP dose was 3 mg/kg throughout. After various periods of withdrawal rats were tested for PPI and LI.
Results
Repeated intermittent treatment with Amp or PCP resulted in augmented locomotor responses to challenge with each drug, providing an operational index that sensitization had occurred. Rats sensitized to Amp showed disrupted PPI when tested drug free at 3, 21 and 60 days of withdrawal. Amp-sensitized rats also showed abolition of the LI effect. Rats sensitized to PCP did not show deficits in any of these behaviours when tested drug free.
Conclusions
Because disrupted PPI and LI have both been reported in schizophrenic patients, these results suggest that the Amp-sensitized state may represent a useful model for investigating the neural bases of information processing deficits in schizophrenia.
Similar content being viewed by others
References
Abi-Dargham A, Moore H (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9:404–416
Akiyama K, Kanzaki A, Tsuchida K, Ujike H (1994) Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophr Res 12:251–257
Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283
Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598–606
Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206–215
Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234–258
Carlsson M, Carlsson A (1990) Interaction between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276
Castner SA, Goldman-Rakic PS (2003) Amphetamine sensitization of hallucinatory–like behaviours is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry 54:105–110
Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241–253
Druhan JP, Geyer MA, Valentino RJ (1998) Lack of sensitization to the effects of d-amphetamine and apormorphine on sensorimotor gating in rats. Psychopharmacology 135:296–304
Ellenbroek BA, Knobbout DA, Cools AR (1997) The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology (Berl) 129:112–120
Escobar M, Oberling P, Miller RR (2002) Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neurosci Biobehav Rev 26:203–216
Greenberg BD, Segal DS (1985) Acute and chronic behavioural interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav 23:99–105
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of model of schizophrenia. Am J Psychiatry 148:1301–1308
Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225
Jentsch JD, Elsworth JD, Redmond DE Jr, Roth RH (1997) Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J Neurosci 17:1769–1775
Jentsch JD, Taylor JR, Roth RH (1998a) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19:105–113
Jentsch JD, Tran A, Taylor JR, Roth RH (1998b) Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioural and neurochemical evidence. Psychopharmacology (Berl) 138:89–95
Johnson KM, Phillips M, Wang C, Kevetter GA (1998) Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52:709–722
Kolta MG, Shreve P, De Souza V, Uretsky NJ (1985) Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology 24:823–829
Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6:869–872
Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 31:371–384
Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine and schizophrenia. Ann N Y Acad Sci 1003:138–158
Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205–229
Lubow RE (1997) Latent inhibition as a measure of learned inattention: some problems and solutions. Behav Brain Res 88:75–83
Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR (1999) Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21:28–39
Murphy CA, Di Iorio L, Feldon J (2001a) Effects of psychostimulant withdrawal on latent inhibition of conditioned active avoidance and prepulse inhibition of the acoustic startle response. Psychopharmacology (Berl) 156:155–164
Murphy CA, Fend M, Russig H, Feldon J (2001b) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 115:1247–1256
Nelson LR, Ellison G (1978) Enhanced stereotypies after repeated injections but not continuous amphetamines. Neuropharmacology 17:1081–1084
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 49:975–982
Phillips M, Wang C, Johnson KM (2001) Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296:905–913
Post RM (1980) Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci 26:1275–1282
Robinson TE (1984) Behavioural sensitization: characterization of enduring changes in rotational behaviour produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology (Berl) 84:466–475
Robinson TE, Becker JB (1986) Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157–198
Russig H, Murphy CA, Feldon J (2002) Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765–777
Sato M, Numachi Y, Hamamura T (1992) Relapse of paranoid psychotic state in methamphetamine model in schizophrenia. Schizophr Bull 18:115–122
Scalzo FM, Holson RR (1992) The ontogeny of behavioural sensitization to phencyclidine. Neurotoxicol Teratol 14:7–14
Schroeder U, Schroeder H, Darius J, Grecksch G, Sabel BA (1998) Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav Brain Res 97:59–68
Schulz B, Fendt M, Pedersen V, Koch M (2001) Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine. Psychopharmacology (Berl) 156:177–181
Solomon PR, Staton DM (1982) Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat’s ability to ignore an irrelevant stimulus. Biol Psychiatry 17:743–756
Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519–537
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M (2003) Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 6:347–352
Tenn CC, Fletcher PJ, Kapur S (2003) Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64:103–114
Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165–179
Turgeon SM, Case LC (2001) The effects of phencyclidine pre-treatment on amphetamine-induced behaviour and c-Fos expression in the rat. Brain Res 888:302–305
Ujike H (2002) Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 4:177–184
Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berl) 114:657–664
Weiner I (2003) The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 169:257–297
Weiner I, Feldon J (1992) Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol Biochem Behav 42:625–631
Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871–878
Xu X, Domino EF (1994) Phencyclidine-induced behavioural sensitization. Pharmacol Biochem Behav 47:603–608
Acknowledgements
This work was supported by a special initiative grant from the Ontario Mental Health Foundation (OMHF). C.T. was supported by a Research Fellowship from the OMHF. S.K. is supported by a Canadian Research Chair in Schizophrenia and Therapeutic Neuroscience.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tenn, C.C., Kapur, S. & Fletcher, P.J. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology 180, 366–376 (2005). https://doi.org/10.1007/s00213-005-2253-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-2253-z